College Stock: Penny Stock News

Friday’s news from $IVOB told the world about the company’s first commercial baby born in Pakistan might be more powerful than some think. The Dean believes this news is significant because $IVOB‘s INVOcell and INVO procedure enabled a 40 year old woman who suffered from infertility for 16 years to become pregnant and have a child. As The Dean has taught the CollegeStock Community, age definitely plays a role in a woman’s inability to become pregnant and $IVOB‘s INVOcell device and INVO procedure has now proven to be effective in an older patient with the transfer of a single embryo. Many women require multiple attempts with IVF treatments, where as many as 6 embryos have been transferred into a patient’s uterus—as in the case of Nadya Suleman also know as “Octomom.” With infertility affecting an estimated 150 million couples around the world, the infertility treatment market is certainly worth talking about. But, as with many things, the spotlight has been turned towards infertility and IVF treatments because of multiple birth pregnancies, aging celebrities and embryo mix-ups. So it almost comes as no surprise that The New York Times has been publishing articles as part of a running commentary on IVF and its surrounding issues. In “The Trouble With Twin Births” section, Josephine Johnston, a lawyer and bioethics researcher, references Nadya Suleman’s IVF procedure, which used 6 embryos and resulted in octuplets, because it calls into question the lack of laws which limit the number of embryos that can be transferred during a single procedure. Johnston suggests that the goal “of all in vitro fertilizations” should be the birth of a single healthy child. By reading through her commentary, The Dean found that limits on the number of embryos transferred have been set in countries in Europe such as Belgium where legislation requires women under the age of 36 to receive only one embryo at a time. Countries like Sweden and Finland also promote single embryo transfers and this has reduced multiple birth pregnancies and success rates are fairly high. Others reporting on the multiple birth and IVF debate, such as Rebecca Dresser, professor of law and ethics at Washington University, believe that health and safety reasons should offer enough support to limit the number of embryos transferred but in countries where IVF isn’t regulated or covered by government funding or insurance this would be difficult. Over the past few months, The Dean has been teaching the CollegeStock Community that IVF treatments can be extremely expensive. But, some couples are willing and able to pay $12,000 or $15,000 for a single, often unsuccessful procedure to have a child. However, Dresser makes a point to say that many of these couples are not aware of the risks of utilizing costly IVF procedures to become parents. With so much buzz around the IVF debate, The Dean’s confident that this will remain a topic of research and debate for years to come. The Dean agrees with both Johnston and Dresser who point to IVF’s price tag as the reason for couples to assume the risk of complications and medical costs associated with multiple birth pregnancies. The Dean believes that the high cost of IVF just may be the only thing keeping IVF unregulated by the government and uncovered by insurance in most parts of the world. The Dean believes that $IVOB‘s INVOcell device and INVO procedure make for an effective, inexpensive IVF treatment that limits the number of embryos transferred and potential for multiple births.